Powered by

Novartis reshapes itself through GSK, Eli Lilly deals

Apr 22, 2014 - The Deal Pipeline

The battle against cancer has taken on a financial dimension, with Novartis SA agreeing to take a host of oncology drugs from GlaxoSmithKline plc in the largest of four multibillion-dollar transactions by the Swiss company, and Pfizer Inc. reportedly missing out in a run for AstraZeneca plc 's cancer treatments.

Novartis, of Basel, on Tuesday agreed to pay up to $16 billion for Uxbridge, England-based GlaxoSmithKline's oncology portfolio. The figure includes as much as $1.5 billion dep...